spacer
home > ict > winter 2017 > up and coming
PUBLICATIONS
International Clinical Trials

Up and Coming

In Sub-Saharan Africa, South Africa remains the optimal location for trials. It accounts for approximately 58% of the total clinical studies conducted within the region and continues to operate as a regional hub. South Africa’s regulatory framework and relatively high level of healthcare infrastructure and public health system make it attractive for trials (1).

The majority of trials that take place in Sub-Saharan Africa are grant-funded and focus on infectious diseases such as HIV, tuberculosis (TB) and malaria. Countries like Burkina Faso, Ghana, Kenya, Malawi, Mali and Tanzania are emerging as viable locations. Both pharmaceutical companies and CROs have been expanding their presence throughout Kenya in the east and Ghana in the west, whereas Nigeria is emerging as a satellite hub to support the growth of clinical trials in this region. Efforts should be taken to harmonise regulatory protocols for the conduct of studies across the continent as most of the guidelines currently vary from country to country.

Development Opportunities

To promote the conduct of clinical research in the region, the Pan African Clinical Trials Registry (PACTR) was established by the South African Cochrane Centre in collaboration with the European and Developing Countries Clinical Trials Partnership and the Cochrane Infectious Disease Group. It is an official registry affiliated with the WHO Network of Primary Registers. The PACTR also provides data to the central WHO International Clinical Trials Registry Platform, so that studies listed in the archive are available through a global platform (2).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Saravanan Thangaraj is a Senior Research Analyst in the Transformational Health group at Frost & Sullivan. He has over three years of experience in management consulting, has advised clients on strategy and business and has also authored many off-the-shelf industry insight reports during his time at the company. Saravanan’s experience includes biotechnology, pharma, life sciences, in vitro diagnostic devices and health systems. He holds a Bachelor of Technology in Biotechnology and a Master of Business Administration from PSG College of Technology, India.
spacer
Saravanan Thangaraj
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BBI Solutions broadens antibody portfolio and strengthens reagent technical support capabilities with acquisition of Maine Biotechnology Services

BBI, a leading manufacturer of raw materials and finished test platforms, already provides human antigens, antibodies, serum and plasma products and clinical chemistry enzymes, for the in-vitro diagnostics market. Now with the acquisition of MBS they have strengthened their antibody offering, providing a comprehensive portfolio and custom services to deliver a total reagent solution for any immunoassay development.
More info >>

White Papers

What is process characterization?

EXPUTEC

Process characterization is an essential step in the commercialization of a new (biological) drug. For drug product commercialization, manufacturers must validate the drug’s manufacturing process. This ensures that the manufacturing process delivers consistently a quality product and that the patient is not at risk.
More info >>

 
Industry Events

5th Annual Peptides Congress 2018

16-17 April 2018, Novotel London West Hotel, Hammersmith, London

Oxford Global Conferences are proud to present our highly anticipated 5th Annual Peptides Congress, 16th– 17th April 2018, London, UK. Over 450 peptides, proteins and antibodies attendees representing global pharmaceutical organizations, leading biotech companies and internationally renowned academic institutions.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement